CVS Health Launches Company To Produce Cheaper Versions of Expensive Biotech Drugs
August 24, 2023
CVS Health has introduced Cordavis, a new subsidiary aimed at producing and commercializing “biosimilar” drugs, which are more affordable versions of costly brand prescriptions derived from biotechnology. Cordavis will collaborate directly with drug manufacturers to develop and distribute these biosimilar products, which are approved by the FDA as highly similar and without clinically meaningful differences from existing brand biologic medicines. CVS aims to ensure a consistent and affordable supply of these biosimilars to enhance patient accessibility to vital treatments while reducing costs.
Recent News
Peloton CEO Steps Down and Layoffs Begin
Peloton, the popular fitness technology company, has announced significant changes in its leadership and organizational structure.
California Restaurants Must Start Eliminating Special Surcharges
Starting July 1, California is changing the game for restaurant bills.
T-Mobile Now Owns Ryan Reynolds-Backed Mint Mobile
The deal is worth upwards of $1.35 billion.
Chipotle Is Giving Away Over $1 Million in Burritos to Healthcare Workers
In acknowledgment of the tireless contributions of healthcare workers, Chipotle Mexican Grill has announced a notable gesture of appreciation: the distribution of 100,000 free burrito e-cards.